The findings suggest that ANGPTL3 inhibitors mitigate the risk of CKD by modulating the immune cell phenotype of HLA-DR on CD14+ CD16+ monocytes (Mediated proportion: 4.69%; Mediated effect: -0.00899) (Supplementary Figure 11, Supplementary Table 16), although the mediating effect remains relatively modest. The gene discussed is ANGPTL3; the disease is chronic kidney disease.